Bevacizumab in lung cancer: hurdles in clinical development

被引：2
|
作者：
Pirker, Robert [1 ]
机构：
[1] Med Univ Vienna, Dept Med 1, A-1090 Vienna, Austria
来源：
LANCET ONCOLOGY | 2010年 / 11卷 / 08期
关键词：
CARBOPLATIN; PACLITAXEL;
D O I：
10.1016/S1470-2045(10)70173-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：703 / 704
页数：2
相关论文
共 50 条
  • [41] Clinical development of Src tyrosine kinase inhibitors in lung cancer
    Lee, David
    Gautschi, Oliver
    [J]. CLINICAL LUNG CANCER, 2006, 7 (06) : 381 - 384
  • [42] Understanding the Hurdles in Lung Cancer Immunotherapy in the Context of Chronic Obstructive Pulmonary Disease
    Salehi-Rad, Ramin
    Dubinett, Steven M.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 198 (07) : 835 - 837
  • [43] Active, specific immunotherapy for lung cancer: Hurdles and strategies using genetic modification
    Korst, RJ
    Crystal, RG
    [J]. ANNALS OF THORACIC SURGERY, 2003, 76 (04): : 1319 - 1326
  • [44] Jumping over Hurdles: Palliative Care Pilot Project in Advanced Lung Cancer
    Davis, Mary Helen
    Padgett, Lynn
    Frantz, Virginia
    Roberts, Christy
    Stallings, Holley
    Shelton, Brent
    Shearer, Andrew
    [J]. PSYCHO-ONCOLOGY, 2015, 24 : 243 - 243
  • [45] Immunological hurdles to lung gene therapy
    Ferrari, S
    Griesenbach, U
    Geddes, DM
    Alton, E
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2003, 132 (01): : 1 - 8
  • [46] Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer
    Thomas, Michael
    Fischer, Juergen
    Andreas, Stefan
    Kortsik, Cornelius
    Grah, Christian
    Serke, Monika
    von Eiff, Michael
    Witt, Christian
    Kollmeier, Jens
    Mueller, Ernst
    Schenk, Michael
    Schroeder, Michael
    Villalobos, Matthias
    Reinmuth, Niels
    Penzel, Roland
    Schnabel, Philipp
    Acker, Thomas
    Reuss, Alexander
    Wolf, Martin
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2015, 46 (01) : 219 - 229
  • [47] Clinical predictors of bevacizumab-associated intestinal perforation in non-small cell lung cancer.
    Tamiya, Motohiro
    Suzuki, Hidekazu
    Shiroyama, Takayuki
    Tanaka, Ayako
    Morishita, Naoko
    Okamoto, Norio
    Sakai, Kenichi
    Shigeoka, Hironori
    Kawahara, Kunimitsu
    Hirashima, Tomonori
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [48] INDIRECT COMPARISON BETWEEN REAL WORLD DATA AND CLINICAL TRIAL IN NON SMALL CELL LUNG CANCER WITH BEVACIZUMAB
    Chamard, P.
    Pau, D.
    Dupin, J.
    [J]. VALUE IN HEALTH, 2019, 22 : S522 - S522
  • [49] Hurdles in the development of a new drug
    Vokes, Everett E.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S301 - S301
  • [50] Ongoing trials with bevacizumab and other antiangiogenic agents in lung cancer
    Dowlati, Afshin
    [J]. CLINICAL LUNG CANCER, 2008, 9 : S71 - S75
12345